121 related articles for article (PubMed ID: 17905804)
1. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats.
Waanders F; van den Berg E; Nagai R; van Veen I; Navis G; van Goor H
Nephrol Dial Transplant; 2008 Feb; 23(2):518-24. PubMed ID: 17905804
[TBL] [Abstract][Full Text] [Related]
2. Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
Waanders F; van Goor H; Navis G
Kidney Blood Press Res; 2008; 31(5):350-9. PubMed ID: 19018148
[TBL] [Abstract][Full Text] [Related]
3. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.
Alderson NL; Chachich ME; Youssef NN; Beattie RJ; Nachtigal M; Thorpe SR; Baynes JW
Kidney Int; 2003 Jun; 63(6):2123-33. PubMed ID: 12753299
[TBL] [Abstract][Full Text] [Related]
4. Strain differences in angiotensin-converting enzyme and angiotensin II type I receptor expression. Possible implications for experimental chronic renal transplant failure.
Smit-van Oosten A; Henning RH; van Goor H
J Renin Angiotensin Aldosterone Syst; 2002 Mar; 3(1):46-53. PubMed ID: 11984748
[TBL] [Abstract][Full Text] [Related]
5. Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats.
Waanders F; Greven WL; Baynes JW; Thorpe SR; Kramer AB; Nagai R; Sakata N; van Goor H; Navis G
Nephrol Dial Transplant; 2005 Oct; 20(10):2060-70. PubMed ID: 15956058
[TBL] [Abstract][Full Text] [Related]
6. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.
Sugimoto H; Grahovac G; Zeisberg M; Kalluri R
Diabetes; 2007 Jul; 56(7):1825-33. PubMed ID: 17456853
[TBL] [Abstract][Full Text] [Related]
7. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
[TBL] [Abstract][Full Text] [Related]
8. A new alloantigen-independent control for chronic allograft nephropathy rat models.
Chang SH; Park HK; Eryilmaz R; Bu D; Stone JJ; Massey D; Riley RS; Fisher RA
J Surg Res; 2005 Sep; 128(1):50-4. PubMed ID: 16115492
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats.
Yamagishi S; Takeuchi M; Inoue H
Int J Tissue React; 2005; 27(3):137-43. PubMed ID: 16372480
[TBL] [Abstract][Full Text] [Related]
10. Protective effects of atorvastatin on chronic allograft nephropathy in rats.
Zhang W; Liu M; Wu Y; Zhu P; Yin C; Zhang W; Gu M
J Surg Res; 2007 Dec; 143(2):428-36. PubMed ID: 17628598
[TBL] [Abstract][Full Text] [Related]
11. AGE formation blockade with aminoguanidine does not ameliorate chronic allograft nephropathy.
Schmaderer C; Xing CJ; Anderson G; Hermans R; Lutz J; Heemann U; Baumann M
Life Sci; 2011 Sep; 89(11-12):349-54. PubMed ID: 21763321
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy.
Elseweidy MM; Elswefy SE; Younis NN; Zaghloul MS
Exp Biol Med (Maywood); 2013 Aug; 238(8):881-8. PubMed ID: 23970406
[TBL] [Abstract][Full Text] [Related]
13. Macrophage-derived interleukin-18 in experimental renal allograft rejection.
Wyburn K; Wu H; Yin J; Jose M; Eris J; Chadban S
Nephrol Dial Transplant; 2005 Apr; 20(4):699-706. PubMed ID: 15716294
[TBL] [Abstract][Full Text] [Related]
14. Ultrastructural analysis of the Fisher to Lewis rat model of chronic allograft nephropathy.
Hamar P; Lipták P; Heemann U; Iványi B
Transpl Int; 2005 Jul; 18(7):863-70. PubMed ID: 15948867
[TBL] [Abstract][Full Text] [Related]
15. Renal N(epsilon)-carboxymethyllysine deposition after kidney transplantation.
Baumann M; Caron M; Schmaderer C; Schulte C; Viklicky O; von Weyhern CW; Lutz J; Heemann U
Transplantation; 2008 Jul; 86(2):330-5. PubMed ID: 18645498
[TBL] [Abstract][Full Text] [Related]
16. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats.
Waanders F; Rienstra H; Boer MW; Zandvoort A; Rozing J; Navis G; van Goor H; Hillebrands JL
Am J Physiol Renal Physiol; 2009 May; 296(5):F1072-9. PubMed ID: 19244402
[TBL] [Abstract][Full Text] [Related]
18. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats.
Boor P; Celec P; Behuliak M; Grancic P; Kebis A; Kukan M; Pronayová N; Liptaj T; Ostendorf T; Sebeková K
Metabolism; 2009 Nov; 58(11):1669-77. PubMed ID: 19608208
[TBL] [Abstract][Full Text] [Related]
19. Fisher-Lewis kidney transplantation model as a tool for investigation of transplantation-induced cardiomyopathy.
Baumann M; Chang J; Thürmel K; Roos M; von Eynatten M; Sollinger D; Lutz J; Heemann U
Transplant Proc; 2009; 41(6):2612-5. PubMed ID: 19715985
[TBL] [Abstract][Full Text] [Related]
20. A combination of Chinese herbs, Astragalus membranaceus var. mongholicus and Angelica sinensis, improved renal microvascular insufficiency in 5/6 nephrectomized rats.
Song J; Meng L; Li S; Qu L; Li X
Vascul Pharmacol; 2009; 50(5-6):185-93. PubMed ID: 19563735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
